US12576117B2 - Antiviral agent - Google Patents

Antiviral agent

Info

Publication number
US12576117B2
US12576117B2 US17/925,333 US202117925333A US12576117B2 US 12576117 B2 US12576117 B2 US 12576117B2 US 202117925333 A US202117925333 A US 202117925333A US 12576117 B2 US12576117 B2 US 12576117B2
Authority
US
United States
Prior art keywords
strain
case
lactobacillus
antiviral
accession number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/925,333
Other languages
English (en)
Other versions
US20230263845A1 (en
Inventor
Haruki Kitazawa
Hisashi Aso
Wakako Ohtsubo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Publication of US20230263845A1 publication Critical patent/US20230263845A1/en
Application granted granted Critical
Publication of US12576117B2 publication Critical patent/US12576117B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
US17/925,333 2020-05-29 2021-05-28 Antiviral agent Active 2042-09-23 US12576117B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-093820 2020-05-29
JP2020093820 2020-05-29
PCT/JP2021/020382 WO2021241728A1 (ja) 2020-05-29 2021-05-28 抗ウイルス剤

Publications (2)

Publication Number Publication Date
US20230263845A1 US20230263845A1 (en) 2023-08-24
US12576117B2 true US12576117B2 (en) 2026-03-17

Family

ID=78744833

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/925,333 Active 2042-09-23 US12576117B2 (en) 2020-05-29 2021-05-28 Antiviral agent

Country Status (4)

Country Link
US (1) US12576117B2 (https=)
EP (1) EP4159839A4 (https=)
JP (1) JPWO2021241728A1 (https=)
WO (1) WO2021241728A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023048197A1 (https=) * 2021-09-22 2023-03-30
CN121712402A (zh) 2023-08-31 2026-03-20 国立大学法人东北大学 线粒体功能改善剂
CN117343880B (zh) * 2023-12-05 2024-06-21 四川厌氧生物科技有限责任公司 一种唾液宿主关联乳杆菌及其应用
WO2025173692A1 (ja) * 2024-02-16 2025-08-21 国立大学法人東北大学 抗ウイルス剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
WO2015088227A1 (ko) * 2013-12-09 2015-06-18 주식회사쎌바이오텍 신규한 유산균 및 이를 포함하는 영유아의 설사병 예방 또는 치료용 조성물
KR101978455B1 (ko) * 2018-01-03 2019-05-14 대한민국(농촌진흥청장) 락토바실러스 살리바리우스 DJ-sa-01 균주 및 이를 포함하는 면역 증강용 조성물
US20210332323A1 (en) * 2018-07-13 2021-10-28 Cj Cheiljedang Corporation Lactobacillus plantarum cjlp475 strain having antiviral and immunomodulatory effects and composition comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007040446A1 (en) 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
WO2015088227A1 (ko) * 2013-12-09 2015-06-18 주식회사쎌바이오텍 신규한 유산균 및 이를 포함하는 영유아의 설사병 예방 또는 치료용 조성물
KR101978455B1 (ko) * 2018-01-03 2019-05-14 대한민국(농촌진흥청장) 락토바실러스 살리바리우스 DJ-sa-01 균주 및 이를 포함하는 면역 증강용 조성물
US20210332323A1 (en) * 2018-07-13 2021-10-28 Cj Cheiljedang Corporation Lactobacillus plantarum cjlp475 strain having antiviral and immunomodulatory effects and composition comprising the same

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
Albarracin et al., ("Efficient Selection of New Immunobiotic Strains With Antiviral Effects in Local and Distal Mucosal Sites by Using Porcine Intestinal Epitheliocytes", Frontiers in Immunology, vol. 11, Apr. 8, 2020 (Year: 2020). *
Albarracin, Leonardo "Efficient Selection of New Immunobiotic Strains With Antiviral Effects in Local and Distal Mucosal Sites by Using Porcine Intestinal Epitheliocytes", Frontiers in Immunology, vol. 11, Apr. 8, 2020 (Apr. 8, 2020).
Animal Science Journal—https://onlinelibrary.wiley.com/doi/abs/10.1111/asj. 13274 dated May 22, 2020.
Arena et al. "Immunobiosis and probiosis: antimicrobial activity of lactic acid bacteria with a focus on their antiviral and antifungal properties." Applied microbiology and biotechnology 102 (2018): 9949-9958. (Year: 2018). *
GenBank Accession No. CP029616.1 (locus_tag=″LS1_00398″; product=″16S ribosomal RNA″), first available Sep. 24, 2018; accessed Jul. 8, 2025, 2 pages. (Year: 2018). *
GenBank Accession No. GU357500, first available Feb. 9, 2010; accessed Feb. 11, 2025, 2 pages. (Year: 2010). *
Johnson, Jethro S., et al. "Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis." Nature communications 10.1 (2019): 5029.
Kumar, R. V. J. et al., "Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens", Trop. Anim. Health Prod., 2010, vol. 42, pp. 1855-1860. DOI: 10.1007/s11250-010-9648-5 (Year: 2010). *
Kumar, R. V. J. et al., "Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens", Trop. Anim. Health Prod., 2010, vol. 42, pp. 1855-1860.
Machine Generated English Translation of KR-101978455-B1. From Espacenet. Original Published May 14, 2019 (Year: 2019). *
Machine Generated English Translation of WO-2015088227-A1. From Espacenet. Originally Published Jun. 18, 2015 (Year: 2015). *
Masumizu et al., Isolation and Immunocharacterization of Lactobacillus salivarius from the Intestine of Wakame-Fed Pigs to Develop Novel "Immunosynbiotics", Microorganisms, vol. 7(6), 167, Jun. 6, 2019 (Jun. 6, 2019), 17 pages, DOI: 10.3390/microorganisms7060167 (Year: 2019). *
Masumizu, Y. et al., Isolation and immunocharacterization of Lactobacillus salivarius from the intestine of wakame-fed pigs to develop novel "immunosynbiotics", Microorganisms, 2019, vol. 7, 167.
Microorganisms—https://www.mdpi.com/2076-2607/7/6/167 dated May 22, 2020.
Raftis, E.J. et al., "Unusual genome complexity in Lactobacillus salivarius JCM1046", BMC Genomics, 2014, 15:771.
Shimazu, T. et al., "Addition of Wakame seaweed (Undaria pinnatifida) stalk to animal feed enhances immune response and improves intestinal microflora in pigs", Anim. Sci. J., 2019, vol. 90, pp. 1248-1260.
Villena, Julio "Draft Genome Sequence of Lactobacillus plantarum MPL16, a Wakame—Utilizing Immunobiotic Strain Isolated from Swine Feces", Genome Announcements, vol. 5, No. 10, Mar. 9, 2017 (Mar. 9, 2017).
Zhang, D.Y. et al., "In vitro characterisation of two Lactobacillus strains and evaluation of their suitability as probiotics for growing-finishing pigs", Anim. Prod. Sci., 2019, vol. 59, pp. 1537-1545.
Albarracin et al., ("Efficient Selection of New Immunobiotic Strains With Antiviral Effects in Local and Distal Mucosal Sites by Using Porcine Intestinal Epitheliocytes", Frontiers in Immunology, vol. 11, Apr. 8, 2020 (Year: 2020). *
Albarracin, Leonardo "Efficient Selection of New Immunobiotic Strains With Antiviral Effects in Local and Distal Mucosal Sites by Using Porcine Intestinal Epitheliocytes", Frontiers in Immunology, vol. 11, Apr. 8, 2020 (Apr. 8, 2020).
Animal Science Journal—https://onlinelibrary.wiley.com/doi/abs/10.1111/asj. 13274 dated May 22, 2020.
Arena et al. "Immunobiosis and probiosis: antimicrobial activity of lactic acid bacteria with a focus on their antiviral and antifungal properties." Applied microbiology and biotechnology 102 (2018): 9949-9958. (Year: 2018). *
GenBank Accession No. CP029616.1 (locus_tag=″LS1_00398″; product=″16S ribosomal RNA″), first available Sep. 24, 2018; accessed Jul. 8, 2025, 2 pages. (Year: 2018). *
GenBank Accession No. GU357500, first available Feb. 9, 2010; accessed Feb. 11, 2025, 2 pages. (Year: 2010). *
Johnson, Jethro S., et al. "Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis." Nature communications 10.1 (2019): 5029.
Kumar, R. V. J. et al., "Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens", Trop. Anim. Health Prod., 2010, vol. 42, pp. 1855-1860.
Kumar, R. V. J. et al., "Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens", Trop. Anim. Health Prod., 2010, vol. 42, pp. 1855-1860. DOI: 10.1007/s11250-010-9648-5 (Year: 2010). *
Machine Generated English Translation of KR-101978455-B1. From Espacenet. Original Published May 14, 2019 (Year: 2019). *
Machine Generated English Translation of WO-2015088227-A1. From Espacenet. Originally Published Jun. 18, 2015 (Year: 2015). *
Masumizu et al., Isolation and Immunocharacterization of Lactobacillus salivarius from the Intestine of Wakame-Fed Pigs to Develop Novel "Immunosynbiotics", Microorganisms, vol. 7(6), 167, Jun. 6, 2019 (Jun. 6, 2019), 17 pages, DOI: 10.3390/microorganisms7060167 (Year: 2019). *
Masumizu, Y. et al., Isolation and immunocharacterization of Lactobacillus salivarius from the intestine of wakame-fed pigs to develop novel "immunosynbiotics", Microorganisms, 2019, vol. 7, 167.
Microorganisms—https://www.mdpi.com/2076-2607/7/6/167 dated May 22, 2020.
Raftis, E.J. et al., "Unusual genome complexity in Lactobacillus salivarius JCM1046", BMC Genomics, 2014, 15:771.
Shimazu, T. et al., "Addition of Wakame seaweed (Undaria pinnatifida) stalk to animal feed enhances immune response and improves intestinal microflora in pigs", Anim. Sci. J., 2019, vol. 90, pp. 1248-1260.
Villena, Julio "Draft Genome Sequence of Lactobacillus plantarum MPL16, a Wakame—Utilizing Immunobiotic Strain Isolated from Swine Feces", Genome Announcements, vol. 5, No. 10, Mar. 9, 2017 (Mar. 9, 2017).
Zhang, D.Y. et al., "In vitro characterisation of two Lactobacillus strains and evaluation of their suitability as probiotics for growing-finishing pigs", Anim. Prod. Sci., 2019, vol. 59, pp. 1537-1545.

Also Published As

Publication number Publication date
EP4159839A4 (en) 2024-10-23
JPWO2021241728A1 (https=) 2021-12-02
WO2021241728A1 (ja) 2021-12-02
EP4159839A1 (en) 2023-04-05
US20230263845A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US12576117B2 (en) Antiviral agent
Dong et al. Benefit of dietary supplementation with Bacillus subtilis BYS2 on growth performance, immune response, and disease resistance of broilers
US11013773B2 (en) Lactic acid bacterial strains
Fečkaninová et al. Characterization of two novel lactic acid bacteria isolated from the intestine of rainbow trout (Oncorhynchus mykiss, Walbaum) in Slovakia
Gaudana et al. Probiotic attributes of Lactobacillus strains isolated from food and of human origin
JPH09506625A (ja) サルモネラの調節用の共生体
US8728461B2 (en) Lactic acid bacterium having high immunoglobulin-A-inducing ability
CN102884174B (zh) 肠道免疫抑制剂的筛选方法
Jia et al. Lactobacillus animalis pZL8a: a potential probiotic isolated from pig feces for further research
CN101124318B (zh) 赋予宿主抗病性的新菌株及细菌细胞组合物
Modesto et al. Strategies to augment non-immune system based defence mechanisms against gastrointestinal diseases in pigs
Chauhan et al. A review on probiotics and fish farming
CN115786175B (zh) 一株粘膜乳杆菌及其用途
Takeuchi et al. Lactococcus kimchii extends lifespan and alleviates motility decline in Caenorhabditis elegans through ins-20, an insulin-like peptide gene
JP2026074019A (ja) 抗ウイルス剤
US20240277788A1 (en) Compositions for increasing resilience towards bacterial infections
Kostovova et al. Probiotic bacteria of wild boar origin intended for piglets–An in vitro study
Zhou et al. Liu J, Liu L, Da R, Cheng Y and Han B (2021) Probiotic Potential Analysis and Safety Evaluation of Enterococcus durans A8-1 Isolated From a Healthy Chinese Infant
WO2025173692A1 (ja) 抗ウイルス剤
POOJA STUDY ON ANTIMICROBIAL EFFICACY OF Lactobacillus SPECIES FROM CHICKEN AGAINST Clostridium perfringens AND E. coli
Cheng et al. Bacillus velezensis-fermented postbiotics as feed additives for viral infection control in largemouth bass (Micropterus salmoides)
Hillier Controlling the Public and Animal Health Threat from Campylobacter Infection in Broiler Chickens by Improving Gut Health and Reducing Inflammation
WO2024090413A1 (ja) 乳酸菌、該乳酸菌由来の自然免疫活性化剤及び該乳酸菌を含有する食品
WO2024090415A1 (ja) 乳酸菌、該乳酸菌由来の自然免疫活性化剤及び該乳酸菌を含有する食品
CN120836651A (zh) 一种治疗家禽球虫病的复合微生态饲料添加剂及其应用

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: TOHOKU UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KITAZAWA, HARUKI;ASO, HISASHI;OHTSUBO, WAKAKO;REEL/FRAME:061860/0832

Effective date: 20221027

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE